Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Phase 2 Recruiting
80 enrolled
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase 1/2 Recruiting
80 enrolled
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Phase 1 Recruiting
32 enrolled
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Phase 2 Recruiting
36 enrolled
Tissue Collection for Studies of Lymph Cancer
Recruiting
1,295 enrolled
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Recruiting
500 enrolled
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 1/2 Recruiting
54 enrolled
GRALE
Phase 1 Recruiting
136 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Phase 1/2 Recruiting
12 enrolled
PALS
Phase NA Recruiting
110 enrolled
RADAR
Phase 3 Recruiting
1,042 enrolled
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting
30 enrolled
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting
99,999 enrolled
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Phase 2 Recruiting
24 enrolled
SJFAMILY
Recruiting
1,500 enrolled
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Phase 1 Recruiting
50 enrolled
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Phase 2 Recruiting
84 enrolled
LIFE-L
Phase NA Recruiting
140 enrolled
FIL_A-BEGEV
Phase 1/2 Recruiting
122 enrolled
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
Recruiting
9,999 enrolled
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Phase 2 Recruiting
27 enrolled
VIJAY-1
Phase 1 Recruiting
42 enrolled
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Phase NA Recruiting
24 enrolled
CILESTE
Phase 1 Recruiting
52 enrolled
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1 Recruiting
73 enrolled
FIL_Tisle-HL
Phase 2 Recruiting
28 enrolled
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
Phase 2 Recruiting
33 enrolled
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Phase 2 Recruiting
257 enrolled
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
Recruiting
250 enrolled
HSCT
Phase 2 Recruiting
100 enrolled
Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
Phase 2 Recruiting
178 enrolled
CABAL2
Phase 1 Recruiting
90 enrolled
Personalized NK Cell Therapy in CBT
Phase 2 Recruiting
100 enrolled
BrECADD
Phase 2 Recruiting
48 enrolled
Two Step Haplo With Radiation Conditioning
Phase 2 Recruiting
63 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
Phase 1/2 Recruiting
31 enrolled
Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
Recruiting
100 enrolled
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Phase 1 Recruiting
22 enrolled
FINISH-HL
Phase 2 Recruiting
30 enrolled
PEGASUS
Phase 1 Recruiting
10 enrolled
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
Phase 2 Recruiting
83 enrolled
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 Recruiting
20 enrolled
RELY-30
Phase 1 Recruiting
60 enrolled
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Recruiting
1,500 enrolled
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Phase 1 Recruiting
18 enrolled
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Recruiting
HBO-UBC
Phase 2 Recruiting
64 enrolled
Registry of Older Patients With Cancer
Recruiting
3,000 enrolled